author-photo

Jérôme Fayette

University of Lyon

247

Papers

7929

Citations

Citation Trend

Filter By

Papers (170) Sort By

Journal Conference Others

A Phase 1b trial of prexasertib in combination with chemoradiation in patients with locally advanced head and neck squamous cell carcinoma.

2021 Radiotherapy and Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

2021 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (14)
Radioresistance and genomic alterations in head and neck squamous cell cancer: A sub-analysis of the ProfiLER protocol

2021 Head and Neck-journal for The Sciences and Specialties of The Head and Neck
Show All
- Source
- Cite
- Save
Citations (0)
Gestion de la toxicité cutanée induite par les inhibiteurs du récepteur du facteur de croissance épidermique (iEGFR) dans les carcinomes épidermoïdes de la tête et du cou, le cancer colorectal ou le cancer du poumon

2021
Show All
- Source
- Cite
- Save
Citations (0)
Erratum: Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations (Jun, 10.1200/JCO.20.02903, 2021)

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Prognostic impact of extranodal extension in resected head and neck squamous cell carcinomas in the era of postoperative chemoradiation: A retrospective monocentric study

2021 Oral Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Interim analysis of IMMUNEBOOST-HPV: A multicenter, randomized, open label, phase II study evaluating the feasibility, and tolerance of neoadjuvant nivolumab in high-risk HPV driven oropharynx cancer.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
TPExtreme randomized trial: Quality of Life (QoL) and survival according to second-line treatments in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (9)
Molecular biomarkers to identify patients (pts) who may benefit from durvalumab (D; anti-PD-L1) ± tremelimumab (T; anti-CTLA-4) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) from HAWK and CONDOR studies.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
The Slippery Role of Induction Chemotherapy in Head and Neck Cancer: Myth and Reality

2020 Frontiers in Oncology
Show All
- Source
- Cite
- Save
Citations (12)